Halozyme Therapeutics (HALO) stock price, revenue, and financials

Halozyme Therapeutics market cap is $5.4 b, and annual revenue was $267.59 m in FY 2020

View Company

+4.03(+9.97%)

$5.4 B

HALO Mkt cap, 13-May-2022

$89 M

Halozyme Therapeutics Revenue Q1, 2021

Halozyme Therapeutics Gross profit (Q1, 2021)70.8 M

Halozyme Therapeutics Gross profit margin (Q1, 2021), %79.5%

Halozyme Therapeutics Net income (Q1, 2021)27.9 M

Halozyme Therapeutics EBIT (Q1, 2021)50.7 M

Halozyme Therapeutics Cash, 31-Mar-2021499.5 M

Halozyme Therapeutics EV5.8 B

Halozyme Therapeutics Revenue

Halozyme Therapeutics revenue was $267.59 m in FY, 2020 which is a 36.5% year over year increase from the previous period.

Embed Graph

Halozyme Therapeutics Revenue Breakdown

Embed Graph

Halozyme Therapeutics revenue breakdown by business segment: 33.1% from Royalties, 46.0% from Revenues under Collaborative Agreements and 20.9% from Product Sales

Halozyme Therapeutics revenue breakdown by geographic segment: 40.0% from United States, 7.5% from Belgium, 35.9% from Switzerland, 11.4% from Ireland and 5.3% from Other

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Revenue	151.9m	196.0m	267.6m
Revenue growth, %		29%	37%
Cost of goods sold	10.1m	45.5m	43.4m
Gross profit	141.7m	150.4m	224.2m
Gross profit Margin, %	93%	77%	84%
R&D expense	150.3m	140.8m	34.2m
General and administrative expense	60.8m	77.3m	45.7m
Operating expense total	211.1m	218.1m	80.0m
EBIT	(69.3m)	(67.6m)	144.3m
EBIT margin, %	(46%)	(34%)	54%
Interest expense	18.0m	11.6m	20.4m
Pre tax profit	(79.8m)	(72.3m)	129.3m
Income tax expense	537.0k	(11.0k)	217.0k
Net Income	(80.3m)	(72.2m)	129.1m
EPS	(0.6)	(0.5)	0.9

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Revenue	56.9m	39.1m	46.2m	25.4m	55.2m	65.3m	89.0m
Cost of goods sold	4.6m	1.9m	22.3m	5.8m	5.7m	5.6m	18.2m
Gross profit	52.3m	37.3m	23.9m	19.6m	49.5m	59.7m	70.8m
Gross profit Margin, %	92%	95%	52%	77%	90%	91%	80%
R&D expense	31.3m	33.9m	30.5m	10.2m	9.0m	7.7m	9.0m
General and administrative expense	18.0m	17.3m	18.0m	12.6m	11.0m	11.7m	11.1m
Operating expense total	49.3m	51.2m	48.4m	22.8m	19.9m	19.4m	20.1m
EBIT	3.0m	(14.0m)	(24.5m)	(3.2m)	29.6m	40.3m	50.7m
EBIT margin, %	5%	(36%)	(53%)	(13%)	54%	62%	57%
Interest expense	3.2m	2.6m	2.1m	5.3m	5.0m	5.0m	2.0m
Pre tax profit	1.8m	(14.6m)	(25.0m)	(6.1m)	25.9m	36.3m	28.1m
Income tax expense	22.0k	17.0k	13.0k	11.0k	58.0k	63.0k	191.0k
Net Income	1.8m	(14.6m)	(25.0m)	(6.1m)	25.8m	36.2m	27.9m
EPS	0.0	(0.1)	(0.2)	0.0	0.2	0.3	0.2

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Cash	57.9m	120.2m	147.7m
Accounts Receivable	30.0m	59.4m	97.7m
Prepaid Expenses	20.7m	33.4m	28.3m
Inventories	22.6m	29.4m	60.7m
Current Assets	427.8m	543.4m	554.8m
PP&E	7.5m	10.9m	10.6m
Total Assets	440.2m	565.9m	579.9m
Accounts Payable	4.1m	6.4m	1.9m
Short-term debt	91.5m	19.5m	397.2m
Current Liabilities	149.4m	85.6m	421.4m
Long-term debt	34.9m	383.0m
Total Debt	126.4m	402.6m	397.2m
Common Stock	145.0k	137.0k	135.0k
Additional Paid-in Capital	780.5m	695.1m	625.5m
Retained Earnings	(531.4m)	(603.7m)	(474.6m)
Total Equity	248.9m	91.8m	151.0m
Debt to Equity Ratio	0.5 x	4.4 x	2.6 x
Debt to Assets Ratio	0.3 x	0.7 x	0.7 x
Financial Leverage	1.8 x	6.2 x	3.8 x

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Cash	60.6m	67.0m	59.2m	104.8m	133.6m	65.7m	499.5m
Accounts Receivable	28.2m	32.2m	40.7m	29.7m	37.4m	62.6m	88.4m
Prepaid Expenses	20.9m	28.1m	27.2m	28.6m	29.2m	31.9m	30.7m
Inventories	31.2m	43.9m	36.1m	41.5m	48.3m	57.7m	58.3m
Current Assets	409.0m	391.7m	342.0m	468.0m	500.4m	498.9m	941.7m
PP&E	14.5m	15.1m	15.4m	11.8m	11.2m	10.3m	10.4m
Total Assets	429.1m	417.8m	370.4m	492.4m	527.0m	524.0m	966.6m
Accounts Payable	4.1m	12.5m	4.3m	8.3m	4.1m	433.0k	535.0k
Short-term debt	86.7m	70.9m	54.5m	2.9m	390.1m	393.6m	89.0m
Current Liabilities	138.7m	135.4m	108.0m	42.0m	26.1m	27.0m	107.4m
Long-term debt	18.7m	14.1m	9.3m	386.6m			784.7m
Total Debt	105.4m	85.0m	63.8m	389.4m	390.1m	393.6m	873.8m
Common Stock	145.0k	146.0k	147.0k	135.0k	137.0k	135.0k	143.0k
Additional Paid-in Capital	789.5m	803.8m	814.1m	667.7m	688.3m	646.2m	501.2m
Retained Earnings	(529.6m)	(544.3m)	(569.3m)	(609.8m)	(584.0m)	(547.8m)	(433.7m)
Total Equity	260.0m	260.1m	245.4m	58.0m	105.6m	99.0m	67.6m
Debt to Equity Ratio	0.4 x	0.3 x	0.3 x	6.7 x	3.7 x	4 x	12.9 x
Debt to Assets Ratio	0.2 x	0.2 x	0.2 x	0.8 x	0.7 x	0.8 x	0.9 x
Financial Leverage	1.7 x	1.6 x	1.5 x	8.5 x	5 x	5.3 x	14.3 x

Annual

USD	FY, 2018	FY, 2019	FY, 2020
Net Income	(80.3m)	(72.2m)	129.1m
Depreciation and Amortization	2.4m	4.1m	3.3m
Accounts Receivable	11.6m	(29.4m)	(38.3m)
Inventories	(17.5m)	(6.7m)	(31.4m)
Accounts Payable	5.7m	4.6m	(41.2m)
Cash From Operating Activities	(49.5m)	(85.4m)	55.5m
Purchases of PP&E	(4.7m)	(4.0m)	(2.5m)
Cash From Investing Activities	2.5m	(5.5m)	78.4m
Long-term Borrowings	(77.5m)	(108.1m)	(19.6m)
Cash From Financing Activities	(63.8m)	153.2m	(106.3m)
Net Change in Cash	(110.8m)	62.2m	27.5m
Interest Paid	16.9m	9.0m	6.5m
Income Taxes Paid	220.0k	188.0k	180.0k

Quarterly

USD	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020	Q3, 2020	Q1, 2021
Net Income	1.8m	(12.8m)	(37.8m)	(6.1m)	19.7m	55.9m	27.9m
Depreciation and Amortization	990.0k	2.0m	3.0m	857.0k	1.7m	2.5m	738.0k
Accounts Receivable	1.8m	(2.2m)	(10.7m)	29.7m	22.0m	(3.1m)	9.3m
Inventories	(8.6m)	(21.3m)	(13.4m)	(12.1m)	(18.9m)	(28.3m)	2.5m
Accounts Payable	(7.9m)	1.7m	(6.8m)	(27.6m)	(37.5m)	(40.1m)	(6.6m)
Cash From Operating Activities	(4.4m)	(29.2m)	(58.8m)	(4.8m)	(1.5m)	4.5m	58.3m
Purchases of PP&E	(927.0k)	(2.3m)	(3.4m)	(114.0k)	(629.0k)	(805.0k)	(270.0k)
Cash From Investing Activities	28.8m	76.3m	117.3m	38.1m	50.0m	19.9m	(45.2m)
Long-term Borrowings	(21.3m)	(42.0m)	(63.3m)	(16.7m)	(19.6m)	(19.6m)	(369.1m)
Cash From Financing Activities	(21.7m)	(38.0m)	(57.2m)	(48.6m)	(35.0m)	(78.9m)	338.7m
Net Change in Cash	2.7m	9.1m	1.3m	(15.4m)	13.4m	(54.4m)	351.7m

USD	FY, 2018
Revenue/Employee	595.5k
Debt/Equity	0.5 x
Debt/Assets	0.3 x
Financial Leverage	1.8 x

	FY, 2018	FY, 2019	FY, 2020
Products	1	1	1
Partnered Products	3	3	5
Filed Trials Products		2
Phase III Trials Products	5	3	8
Phase II Trials Products	1	1	1
Phase I Trials Products	10	9	10
Preclinical Phase Products	2
Patents (US)	39	43	43
Patents (Europe)	390	520	460
Patent Applications	100	70	50